LISATA THERAPEUTICS, INC. (LSTA) is a clinical-stage pharmaceutical company with no revenue and a going-concern qualification as of March 31, 2026. Under the liquidation lens, recovery to equity is marginally positive but deteriorating rapidly given cash burn. The MFFAIS liquidation value is reported at $12.9 million across all three measures (CLV/LLV/OLV), consistent with the balance sheet position described in the filing: cash and cash equivalents of approximately $13.1 million as of March 31, 2026, with $8.75 million of that held in Level 1 available-for-sale debt securities classified as cash equivalents (money market/short-duration instruments, all maturing within one year, zero unrealized gain/loss). Total cash and marketable securities per the segment disclosure is $13.1 million at March 31, 2026, down from $25.8 million as of March 31, 2025—a decline of approximately $12.7 million over twelve months, implying a run-rate cash consumption of roughly $12-13 million per year. Quarterly operating cash burn in Q1 2026 was $3.1 million versus $5.4 million in Q1 2025, reflecting the wind-down of the BOLSTER trial and headcount reduction. At $3.1 million per quarter, current cash of $13.1 million provides approximately 4 quarters of runway absent the pending Kuva Labs acquisition. PP&E net book value is de minimis at $16 thousand (computer equipment 97% depreciated). Accrued liabilities increased to $2.8 million from $2.1 million at December 31, 2025, driven by a $458 thousand increase in employee compensation accruals and a $370 thousand increase in legal liabilities, the latter attributable to transaction costs related to the proposed Kuva Labs merger. There is no funded debt, no pension, and no disclosed operating lease obligations on the balance sheet, which keeps the liability stack clean. The asset side is almost entirely cash and near-cash; intangibles (certepetide IP, SBP license) carry zero recovery value under the liquidation lens. The Qilu collaboration was terminated January 23, 2026, eliminating a potential $200 million milestone stream but also removing any associated liability. The pending Kuva Labs merger ($5.00/share cash plus a $1.00 CVR) has not closed; Purchaser had not commenced the tender offer as of the filing date (May 11, 2026), with the deadline extended to May 29, 2026. If the deal fails, equity holders face a going-concern scenario with limited runway and no near-term revenue. Filing discusses the Australia R&D tax incentive receivable ($0.2 million at March 31, 2026, down from $0.7 million) in narrative and Note 12 but does not emit a separate XBRL tag for this line in TAG_CONTEXT. The TAG_CONTEXT list provided is empty, so no XBRL-specific tag_insights can be populated per the schema rules. All material balance-sheet items are addressed in this narrative.
▼ Community Notes